| Publications | PubMed=7028788; DOI=10.1172/JCI110380
Bast R.C. Jr., Feeney M., Lazarus H., Nadler L.M., Colvin R.B., Knapp R.C.
Reactivity of a monoclonal antibody with human ovarian carcinoma.
J. Clin. Invest. 68:1331-1337(1981) PubMed=6346879; DOI=10.1016/0002-9378(83)90999-7
Berkowitz R.S., Kabawat S., Lazarus H., Colvin R.B., Knapp R.C., Bast R.C. Jr.
Comparison of a rabbit heteroantiserum and a murine monoclonal antibody raised against a human epithelial ovarian carcinoma cell line.
Am. J. Obstet. Gynecol. 146:607-612(1983) PubMed=1536252; DOI=10.1016/0002-9378(92)91697-9
Berchuck A., Rodriguez G., Olt G., Whitaker R., Boente M.P., Arrick B.A., Clarke-Pearson D.L., Bast R.C. Jr.
Regulation of growth of normal ovarian epithelial cells and ovarian cancer cell lines by transforming growth factor-beta.
Am. J. Obstet. Gynecol. 166:676-684(1992) PubMed=7836420; DOI=10.1074/jbc.270.3.999
Young T.N., Pizzo S.V., Stack M.S.
A plasma membrane-associated component of ovarian adenocarcinoma cells enhances the catalytic efficiency of matrix metalloproteinase-2.
J. Biol. Chem. 270:999-1002(1995) PubMed=10318951; DOI=10.1073/pnas.96.10.5722
Lau K.-M., Mok S.C., Ho S.-M.
Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells.
Proc. Natl. Acad. Sci. U.S.A. 96:5722-5727(1999) PubMed=10972993; DOI=10.1002/1098-2744(200008)28:4<236::AID-MC6>3.0.CO;2-H
Rauh-Adelmann C., Lau K.-M., Sabeti N., Long J.P., Mok S.C., Ho S.-M.
Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines.
Mol. Carcinog. 28:236-246(2000) PubMed=11793438; DOI=10.1002/gcc.1221
Rao P.H., Harris C.P., Lu X.-Y., Li X.-N., Mok S.C., Lau C.C.
Multicolor spectral karyotyping of serous ovarian adenocarcinoma.
Genes Chromosomes Cancer 33:123-132(2002) PubMed=12960427; DOI=10.1091/mbc.E03-05-0279
Schaner M.E., Ross D.T., Ciaravino G., Sorlie T., Troyanskaya O.G., Diehn M., Wang Y.C., Duran G.E., Sikic T.L., Caldeira S., Skomedal H., Tu I.-P., Hernandez-Boussard T., Johnson S.W., O'Dwyer P.J., Fero M.J., Kristensen G.B., Borresen-Dale A.-L., Hastie T., Tibshirani R., van de Rijn M., Teng N.N.H., Longacre T.A., Botstein D., Brown P.O., Sikic B.I.
Gene expression patterns in ovarian carcinomas.
Mol. Biol. Cell 14:4376-4386(2003) PubMed=20204287; DOI=10.3892/or_00000728
Langland G.T., Yannone S.M., Langland R.A., Nakao A., Guan Y.-H., Long S.B.T., Vonguyen L., Chen D.J., Gray J.W., Chen F.-Q.
Radiosensitivity profiles from a panel of ovarian cancer cell lines exhibiting genetic alterations in p53 and disparate DNA-dependent protein kinase activities.
Oncol. Rep. 23:1021-1026(2010) PubMed=22585861; DOI=10.1158/2159-8290.CD-11-0224
Marcotte R., Brown K.R., Suarez Saiz F.J., Sayad A., Karamboulas K., Krzyzanowski P.M., Sircoulomb F., Medrano M., Fedyshyn Y., Koh J.L.Y., van Dyk D., Fedyshyn B., Luhova M., Brito G.C., Vizeacoumar F.J., Vizeacoumar F.S., Datti A., Kasimer D., Buzina A., Mero P., Misquitta C., Normand J., Haider M., Ketela T., Wrana J.L., Rottapel R., Neel B.G., Moffat J.
Essential gene profiles in breast, pancreatic, and ovarian cancer cells.
Cancer Discov. 2:172-189(2012) PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017
Korch C.T., Spillman M.A., Jackson T.A., Jacobsen B.M., Murphy S.K., Lessey B.A., Jordan V.C., Bradford A.P.
DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination.
Gynecol. Oncol. 127:241-248(2012) PubMed=23415752; DOI=10.1016/j.molonc.2012.12.007
Stordal B., Timms K., Farrelly A., Gallagher D., Busschots S., Renaud M., Thery J., Williams D., Potter J., Tran T., Korpanty G., Cremona M., Carey M.S., Li J., Li Y., Aslan O., O'Leary J.J., Mills G.B., Hennessy B.T.
BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.
Mol. Oncol. 7:567-579(2013) PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015) PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015) PubMed=26589293; DOI=10.1186/s13073-015-0240-5
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015) PubMed=28273451; DOI=10.1016/j.celrep.2017.02.028
Medrano M., Communal L., Brown K.R., Iwanicki M., Normand J., Paterson J., Sircoulomb F., Krzyzanowski P.M., Novak M., Doodnauth S.A., Suarez Saiz F.J., Cullis J., Al-awar R., Neel B.G., McPherson J., Drapkin R.I., Ailles L., Mes-Masson A.-M., Rottapel R.
Interrogation of functional cell-surface markers identifies CD151 dependency in high-grade serous ovarian cancer.
Cell Rep. 18:2343-2358(2017) |
|---|